TITUSVILLE, N.J., Jan. 23 /PRNewswire-FirstCall/ -- Janssen Pharmaceutica Products, L.P., a Johnson & Johnson company, has received a subpoena from the U.S. Office of Personnel Management, Office of the Inspector General requesting documents related to RISPERDAL(R) (risperidone), a prescription medication approved to treat schizophrenia and bipolar mania. The company is cooperating in responding to the subpoena.
Janssen Pharmaceutica Products, L.P.
CONTACT: Press - Doug Arbesfeld, +1-908-218-7592, Investor - Helen E.Short, +1-732-524-6491, Stan Panasewicz, +1-732-524-2524, all of JanssenPharmaceutica Products
Web site: http://www.jnj.com/
Company News On-Call: http://www.prnewswire.com/comp/467347.html
